initial public offerings (IPOs) trading on American exchanges

Tuesday, August 29, 2017

Uniti Group (UNIT)

  • REIT - Industrial
  • Div/yield 0.60/12.35

 





Uniti Group Inc., formerly Communications Sales & Leasing, Inc., is an internally managed real estate investment trust engaged in the acquisition and construction of infrastructure in the communications industry. The Company focuses on acquiring and constructing fiber optic broadband networks, wireless communications towers, copper and coaxial broadband networks and data centers. It operates in four segments: Leasing, Fiber Infrastructure, Towers and Consumer Competitive Local Exchange Carrier (Consumer CLEC). The Leasing segment includes Uniti Leasing. The Fiber Infrastructure segment includes Uniti Fiber business. The Towers segment includes Uniti Towers and its ground lease investments. The Consumer CLEC segment includes Talk America. As of July 3, 2017, the Company and its subsidiaries owned approximately 88,100 fiber network route miles, representing approximately 4.8 million fiber strand miles and approximately 231,900 route miles of copper cable lines across 32 states.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-7.73%-0.03%
Operating margin27.56%35.79%
EBITD margin-88.96%
Return on average assets-1.77%-0.01%
Return on average equity--
Employees316

Long trade : OKTA +18% (8/17)



J. Jill (JILL) reported earnings on Tue 29 Aug 2017 (b/o)

** charts after earnings **

 




J. Jill reports EPS in-line, beats on revs; guides Q3 EPS in-line; raises FY18 EPS guidance and reaffirms FY18 comp guidance; Q2 comps +7.8%
  • Reports Q2 (Jul) earnings of $0.29 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.29; revenues rose 9.9% year/year to $181.4 mln vs the $179.02 mln Capital IQ Consensus. Total company comparable sales, which includes comparable store sales and direct to consumer comparable sales, increased by 7.8%. Gross profit increased to $122.6 million from $112.9 million in the second quarter of fiscal 2016. As a percentage of total net sales, gross profit was 67.6% compared to a record second quarter gross profit of 68.4% in fiscal 2016.
  • Co issues in-line guidance for Q3, sees EPS of $0.18-0.20, excluding non-recurring items, vs. $0.19 Capital IQ Consensus Estimate. Co sees Q3 comps to increase in the high single digits.
  • Co issues raised guidancefor FY18, sees EPS of $0.81-0.85 from $0.80-0.84, excluding non-recurring items, vs. $0.84 Capital IQ Consensus Estimate. In FY18, co expects total comparable sales to increase in the high single digits. The 53rd week of fiscal 2017, which is not included in the 52-week basis outlook given above, is expected to contribute an additional $9.0 million in sales and approximately $0.01 of earnings per share. 

Wednesday, August 23, 2017

YogaWorks (YOGA) began trading on the Nasdaq on 11 August 2017

YogaWorks, Inc. operates yoga studios under the YogaWorks and Yoga Tree brand names in the United States.

  • Founded in 1987 
  • Headquartered in Culver City, California.
  • Sector: Consumer Cyclical
  • Industry: Personal Services
  • Full Time Employees: 1,360
  • http://www.yogaworks.com
  • Share Price $5.50
  • Shares Offered 7,300,000
  • Offer Amount $40,150,000.00


Sienna Biopharmaceuticals (SNNA) started trading on the Nasdaq on 27 July 2017



Sienna Biopharmaceuticals, Inc. is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125. The Company has developed over 70 products. Its SNA-120 and SNA-125 are generated through its Topical by Design platform technology. Its SNA-120 is a Topical Tropomyosin Receptor Kinase A (TrkA) inhibitor for pruritus and psoriasis. Its SNA-125 is a Topical TrkA/Janus Kinase 3 (JAK3) Inhibitor for atopic dermatitis, psoriasis and pruritus. Its SNA-001 is a Topical Photoparticle Therapy for medical and aesthetic applications. Its SNA-001 Topical Photoparticle Therapy is used for localized and non-systemic treatment of acne. Its SNA-001 Topical Photoparticle Therapy is used for reduction of light-pigmented hair.

Address

30699 Russell Ranch Rd Ste 140
WESTLAKE VILLAGE, CA 91362-7327
United States

Monday, August 21, 2017

Thursday, August 17, 2017

Seadrill Partners (SDLP) : 5-year performance

  • Seadrill Partners LLC (NYSE:SDLP) is an MLP formed by the Norwegian offshore oil and gas drilling Seadrill Limited (SDRL)
  • Headquarters: United Kingdom
  • Founded: 2012
  • Div/yield 0.10/12.38
  • Website http://www.seadrillpartners.com

  




  • 2 months later



Seadrill amends certain credit facilities to insulate Seadrill Partners (SDLP) from Seadrill Limited's restructuring
  • Seadrill (SDRL) announces that it has completed amendments to three secured credit facilities that relate to rigs purchased by Seadrill Partners (SDLP) from the Company that will insulate Seadrill Partners from events of default related to the Company's likely use of chapter 11 proceedings to implement its restructuring plan. The amendments to the three facilities remove Seadrill Partners and its consolidated entities as a borrower or guarantor and separate the facilities such that each resulting Seadrill Limited facility is secured only by Seadrill Limited's assets without recourse to Seadrill Partners or its assets.
  • The amendments to the three facilities remove Seadrill Partners and its consolidated entities as a borrower or guarantor and separate the facilities such that each resulting Seadrill Limited facility is secured only by Seadrill Limited's assets without recourse to Seadrill Partners or its assets.
  • As part of this transaction we have agreed to a prepayment of $100 million upon closing and two subsequent prepayments of $25 million, one of which will be made six months after closing and another of which will be made 12 months after closing, in each case distributed pro rata across the three resulting Seadrill Partners facilities.

Monday, August 14, 2017

PetIQ (PETQ) reported earnings Mon 14 Aug 2017 (b/o)


PetIQ reports Q2 results (no estimates)
  • Net income was $6.1 million for Q2 compared to $0.6 million for the prior year period. Adjusted EBITDA increased $4.2 million to $7.6 million.
  • Net sales increased 42.3% to $87.2 million for the second quarter of 2017 compared to $61.3 million for the same period in the prior year

=WideOpenWest (WOW) reported earnings Mon 14 Aug 2017 (b/o)



WideOpenWest beats by $0.03, reports revs in-line
  • Reports Q2 (Jun) earnings of $0.15 per share, excluding non-recurring items, $0.03 better thanthe Capital IQ Consensus of $0.12; revenues fell 3.3% year/year to $297.5 mln vs the $299.23 mln Capital IQ Consensus.
  • As of the second quarter of 2017, WOW! reported total subscribers of 776,500 versus 770,200 in the second quarter of 2016 on a transaction adjusted basis, a 0.8% increase. The sequential decline from 780,100 in the first quarter of 2017 reflects a combination of seasonality and the implementation of the Company's annual price increase during the second quarter.
  • Second quarter 2017 Adjusted EBITDA was $112.2 million, up 1.0%, from the second quarter of 2016 on a transaction adjusted basis. Second quarter 2017 Adjusted EBITDA margin was 37.7% up 97 basis points from the same period a year ago on a transaction adjusted basis.

Friday, August 11, 2017

Ranger Energy Services (RNGR) began trading on the NYSE on 11 August 2017





Description

Ranger Energy Services, Inc. is an independent provider of high-specification (high-spec) well service rigs and associated services in the United States. The Company focuses on unconventional horizontal well completion and production operations. The Company operates through Well Services and Processing Solutions segment. Well Services segment provides high-spec well service rigs and complementary equipment and services in the United States, with a focus on unconventional horizontal well completion, workover and maintenance operations. Processing Solutions segment engages in the rental, installation, commissioning, start-up, operation and maintenance of MRUs, NGL stabilizer units, NGL storage units and related equipment. The Company also offers full transportation, turn-key mobilization services, installation and ongoing operation services in the field. The Company's turn-key mobilization services include in-bound transportation and site offloading.

Address

800 Gessner Rd Ste 1000
HOUSTON, TX 77024-4257
United States

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-17.80%-9.47%
Operating margin-14.54%-8.52%
EBITD margin-3.98%
Return on average assets-14.81%-5.27%
Return on average equity-22.28%-6.54%
Employees663

Thursday, August 10, 2017

Paylocity (PCTY) reported earnings on Thur 10 Aug 2017 (a/h)

** charts before earnings ** 



 



** charts after earnings **





Paylocity beats by $0.08, beats on revs; guides Q1 EPS in-line, revs in-line; guides FY18 EPS in-line, revs in-line(43.35 -1.33)
  • Reports Q4 (Jun) earnings of $0.09 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of $0.01; revenues rose 27.3% year/year to $76.1 mln vs the $73.79 mln Capital IQ Consensus. 
  • Adjusted EBITDA, a non-GAAP measure, was $11.5 million compared to Adjusted EBITDA of $3.3 million in the fourth quarter of fiscal year 2016.
  • Co issues in-line guidancefor Q1, sees EPS of $0.10-0.12, excluding non-recurring items, vs. $0.10 Capital IQ Consensus Estimate; sees Q1 revs of $80.3-81.3 mln vs. $80.66 mln Capital IQ Consensus Estimate.
  • Co issues in-line guidancefor FY18, sees EPS of $0.78-0.80, excluding non-recurring items, vs. $0.78 Capital IQ Consensus Estimate; sees FY18 revs of $368-370 mln vs. $370.78 mln Capital IQ Consensus Estimate.

Contura Energy (CTRA) postpones IPO

Contura Energy postpones IPO; was expected to price 6.0 million shares within a range of $23-$27
The company's principal selling stockholders unanimously determined that proceeding with the offering under current market conditions would undervalue the company. Accordingly, the company has withdrawn its registration statement on file with the U.S. Securities and Exchange Commission (SEC).

  • CTRA is a miner of met and steam coal with its operations comprising of six mining complexes.
  • The IPO was expected to price last night and open for trading this morning.
  • The lead underwriters on the deal were Citigroup and Jefferies.

Wednesday, August 9, 2017

=Zealand Pharma (ZEAL) started trading on the Nasdaq on 9 Aug 2017



Zealand Pharma, a Denmark-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American IPO on July 6th, today marks Zealand’s first day on NASDAQ as it aims for $75M (€63.5M), underwritten by Goldman Sachs and Morgan Stanley, that would bring its market cap to $582M (€493M).

The biotech has successfully sent two type 2 diabetes products to market, a combination of a GLP-1 analog and insulin known as Suliqua in the EU (Soliqua in the US), and a meal-time GLP-1 receptor agonist called Adlyxin (or Lyxumia). Both of these have been licensed to Sanofi for commercialization.

The fresh funds from the NASDAQ offering will go to Zealand Pharma’s clinical trials for glepaglutide, a treatment for Short Bowel Syndrome, and dasiglucagon as a ‘rescue treatment’ for severe hypoglycemia, single-hormone pump for hyperinsulinism, and part an artificial pancreas system, like the one Roman Hovorka is developing.

Zealand Pharma isn’t the only biotech in Denmark staking its name on diabetes treatments. It’s competing directly with Novo Nordisk, the Danish pharma behind a range of insulin-based products, as well as some for obesity and hemophilia. And, as VP Liselotte Hyveled said in February that its latest product Fiasp could be a blockbuster.

Product pipeline:  https://www.zealandpharma.com/product-pipeline/

Cars.com (CARS) began trading on the NYSE on 1 June 2017

The company, which provides car buyers with research and makes money from selling ads to car dealers and automakers, has grown into one of Chicago's largest digital media businesses, with revenue of $633 million last year and a headcount of nearly 1,300, according to a regulatory filing for the IPO.
  • Sector: Consumer Cyclical
  • Industry: Auto & Truck Dealerships
  • Full Time Employees: 1,300
  • CEO Alex Vetter
  • Founded in 1998
  • Headquartered in Chicago, Illinois
  • http://www.cars.com
The company's stock rose nearly 9 percent today to close at $27.28 a share, giving the company a market capitalization of $1.95 billion.


Cars was launched in 1998 by a group of newspapers, including Chicago Tribune's parent, that were eager to hang on to lucrative classified auto advertising. Back then it was a division of now-defunct Chicago-based Classified Ventures. Now it's an advertising juggernaut. Revenue climbed 6 percent last year, lifting net income 11 percent to $176.4 million.


Cars, with a clutch of sites including Auto.com and PickupTrucks.com, plus mobile applications, has grown so much that it's moving into a larger building this month, shifting west from the Loop to the other side of the Chicago River near Union Station

In the twisting corporate history of Cars, Gannett bought out its other newspaper owners in a 2014 deal that valued the digital company at $2.5 billion. Then Gannett split into two companies in 2015, cleaving its newspaper business from a group of digital businesses, including Cars, that became Tegna. Tegna spun off the Cars unit last month.

Tuesday, August 8, 2017

TrueCar Inc. (TRUE) reported earnings on Tue 8 Aug 2017 (a/h)

** charts after earnings **

 





TrueCar beats by $0.01, beats on revs; guides Q3 revs below consensus; guides FY17 revs in-line(19.51 -0.17)
  • Reports Q2 (Jun) earnings of $0.01 per share, excluding non-recurring items, $0.01 better thanthe Capital IQ Consensus of ($0.00); revenues rose 23.2% year/year to $81.82 mln vs the $80.75 mln Capital IQ Consensus.
    • Units were 242,130 in Q2 up 26% YoY
  • Co issues downside guidance for Q3, sees Q3 revs of $85-87 mln vs. $87.3 mln Capital IQ Consensus Estimate. Co guides to units of 265,000-270,000.
  • Co issues in-line guidance for FY17, sees FY17 revs of $325-329 mln vs. $327.23 mln Capital IQ Consensus Estimate. Co guides to units of 975,000 to 985,000, .up from prior guidance of 950-960K.
  • "Despite the bigger picture trends in automotive, we set records in nearly every major financial and operating metric in the second quarter...The momentum that we have been building over the past few quarters at TrueCar is continuing quite nicely."

Monday, August 7, 2017

MyoKardia (MYOK) : positive mid-stage trial results for heart muscle disease



  



MyoKardia Inc. (MYOK) surged on positive mid-stage clinical trial results for its mavacamten therapy. Patients on the therapy met the trial's primary endpoint and key secondary endpoints in the phase 2 trial, the company said. MyoKardia expects to start its next clinical trial by the end of this year, depending on discussions with the Food and Drug Administration. The latest data came from the clinical trial's first patient cohort, in which 11 patients were enrolled and 10 patients completed the study. The one patient in question had a history of atrial fibrillation and experienced an episode of atrial fibrillation during the trial. All other safety problems were mild to moderate, according to MyoKardia, and "a majority of the [adverse events] were deemed to be unrelated to the study drug." The Independent Data Monitoring Committee reviewed the trial's safety data and recommended the study be continued, the company said. Mavacamten is intended for symptomatic, obstructive hypertrophic cardiomyopathy, which occurs when heart muscle cells enlarge and block blood flow, and is a common cause of sudden cardiac arrest, according to the American Heart Association. MyoKardia shares have surged 20.4% over the last three months, compared with a 3.2% rise in the S&P 500 (SPX).